Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells

T Wojcik, E Buczek, K Majzner, A Kolodziejczyk… - Toxicology In Vitro, 2015 - Elsevier
T Wojcik, E Buczek, K Majzner, A Kolodziejczyk, J Miszczyk, P Kaczara, W Kwiatek
Toxicology In Vitro, 2015Elsevier
Although anthracycline antibiotics have been successfully used for nearly half a century in
the treatment of various malignancies, their use is limited by their cardiac and vascular
toxicities, and the mechanisms of these toxicities are still not entirely clear. Herein, we
comprehensively characterized cytotoxic effects of two structurally related anthracyclines,
doxorubicin and daunorubicin. In nanomolar concentrations, both drugs induced DNA
damage and increased nuclear area that were associated with their accumulation in the …
Abstract
Although anthracycline antibiotics have been successfully used for nearly half a century in the treatment of various malignancies, their use is limited by their cardiac and vascular toxicities, and the mechanisms of these toxicities are still not entirely clear. Herein, we comprehensively characterized cytotoxic effects of two structurally related anthracyclines, doxorubicin and daunorubicin. In nanomolar concentrations, both drugs induced DNA damage and increased nuclear area that were associated with their accumulation in the nucleus (doxorubicin ⩾50 nM and daunorubicin ⩾25 nM) as evidence by Raman microspectroscopy at 3820–4245 cm−1. At low micromolar concentrations, doxorubicin (⩾5 μM) and daunorubicin (⩾1 μM) increased the generation of reactive oxygen species, decreased intracellular reduced glutathione, induced an alteration in endothelial elasticity and caused a reorganization of the F-actin cytoskeleton. In isolated mouse aortic rings, doxorubicin (⩾50 μM) was less potent than daunorubicin (⩾5 μM) in impairing the endothelium-dependent response.
In summary, using a comprehensive endothelial profiling approach, we demonstrated clear-cut differences in the potencies to induce endotheliotoxic responses for two structurally similar chemotherapeutics, at a nuclear, cytosolic and membrane levels. Furthermore, our results suggest that the differences in the endothelial toxicities of doxorubicin and daunorubicin are linked to differences in their nuclear accumulation and the DNA damage-triggered response of the endothelium.
Elsevier